Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura (TTP) is usually a fatal disease caused by a deficiency of the metalloproteinase, ADAMTS13, often due to autoimmunity. This leads to the development of pathogenic multimers of von Willebrand factor (vWF), causing an inappropriate interaction of platelets and vWF....
Main Authors: | Ashley Hanlon, Ara Metjian |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-02-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/2040620720902904 |
Similar Items
-
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
by: Elverdi T, et al.
Published: (2019-04-01) -
Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
by: Constantine N. Logothetis, et al.
Published: (2021-07-01) -
Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.
by: Andry Van de Louw, et al.
Published: (2021-01-01) -
Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy
by: Giovanni Di Minno, et al.
Published: (2021-04-01) -
Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
by: L. Kaynar, et al.
Published: (2020-10-01)